NCT00239252View on ClinicalTrials.gov

Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Hepatitis C
Interventions
DRUG

Interferon alfacon-1

Trial Locations (5)

Unknown

Chubu Region

Chugoku Region

Kinki Region

Kyushu Region

Tohoku Region

Sponsors

Collaborators (1)

Schering-Plough
All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT00239252 - Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C | Biotech Hunter | Biotech Hunter